According to a recent study published in JAMA Oncology, obesity is associated with an increased risk of early-onset colorectal cancer (CRC) in women.
A medical doctor from Boston Massachusetts General Hospital conducted a study to determine the occurrence of colorectal cancer in 85,256 women without cancer and inflammatory bowel disease based on data from 25-42 -year-old women .
The researchers discovered 114 cases of early-onset CRC (median age at diagnosis, 45 years) during the study period . For overweight women (body mass index [BMI] , 25-29.9 kg / m² ) and obese women (BMI, ≥30 kg / m²) with standard weight ( BMI is 18.5-22.9 kg / m² ) compared with women, CRC increased risk . This finding can be attributed to BMI at 18 years of age and weight gain after 18 years of age. For every 5 units of BMI increase , the RR (relative risk) of colorectal cancer increases by 1.2 . Comparative 18 years old BMI was 18.5-20.9 kg m² / female, BMI is 21 – 22.9 kg / m² women, early onset CRC of RRIs 1.32 , BMI is ≥23kg female RR was 1.63 . Similarly, compared with women who gained less than 5 kg or lost weight, women had an increase of 20-39.9 kg in early-onset CRC with an RR of 1.65 , women with an increase of ≥40 kg and an RR of 2.15.
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.
Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.
Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.
Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.
These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.
Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.
